Advertisement
Chris Novak, NanoLogix Director of IP stated: "The strength and improvedfocus of the new foreign cases arose from significant improvements to theoriginally filed provisional patent applications. We at NanoLogix are veryexcited about the potential for enhancing the patent protection for these newtechnologies."
Advertisement
According to Bret Barnhizer, NanoLogix President and CEO, "This is a stepforward for the company in its plans for technological and businessdevelopment and sets the stage for one of our corporate goals of pursuinglicensing opportunities for use of our products internationally. Theseapplications aid us by ensuring that NanoLogix strengthens their control overthe intellectual property rights to the technology."
About NanoLogix, Inc.
NanoLogix is a leading innovator in the research, development, andcommercialization of nano-biotechnologies, applications and processes. TheCompany has 31 granted Patents and 36 Patents Pending for bioreactor-basedHydrogen Production, revolutionary rapid medical testing technologies,potential treatments for sepsis and cancer (via apoptosis), andbioremediation. Information on NanoLogix is available atwww.nanologixinc.com.
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and theSecurities Exchange Act of 1934, as amended by the Private SecuritiesLitigation Reform Act of 1995. Those statements include statements regardingthe intent, belief or current expectations of NanoLogix, Inc., and members ofits management as well as the assumptions on which such statements are based.Prospective investors are cautioned that any such forward-looking statementsare not guarantees of future performance and involve risks and uncertainties,and that actual results may differ materially from those contemplated by suchforward-looking statements. The Company undertakes no obligation to update orrevise forward-looking statements to reflect changed assumptions, theoccurrence of unanticipated events or changes to future operating results.Contact: Investor Relations Bret Barnhizer, CEO Telephone: 330-534-0800 E-mail: [email protected]
SOURCE NanoLogix, Inc.
